Second-line and third-line antianginal drugs
| Drug name | Mechanism of action |
| Nicorandil | KATP channel opener, vasodilator (conductance and resistance vessels), cardioprotection, ↓LV preload and afterload, no tolerance |
| Ivabradine | I f current inhibition, reduced automaticity of SA node cells, selective slowing of heart rate |
| Ranolazine | Late I Na current inhibition, reduced calcium overload and LV wall tension, improved myocardial perfusion, partial inhibition mitochondrial fatty acid metabolism |
| Trimetazidine | Reversible 3-ketoacyl-thiolase inhibition, reduced mitochondrial fatty acid oxidation |
| Perhexiline | O-Palmitoyltransferase 1/2 inhibition, reduced free fatty acid oxidation and transport into mitochondria |
| Allopurinol | Xanthine oxidase inhibition, reduces oxygen wasting, endothelial dysfunction, substrate depletion |
| Molsidomine | NO donor, vasodilatation |
| Fasudil/hydroxyfasudil | Rho-kinase inhibition, maintains coronary vasodilatation |
| L-Arginine | NO donor, vasodilatation |